Alterity Therapeutics to Present at the Virtual Bell Potter Healthcare Conference MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 12 November 2026: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying...
Alterity to Present at Bell Potter Healthcare Conference
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Alterity Therapeutics Ltd. announced its participation in the virtual Bell Potter Healthcare Conference, where CEO David Stamler will present. The presentation is scheduled for a specific time in November. Alterity is focused on developing treatments for neurodegenerative diseases, particularly Multiple System Atrophy. The announcement was authorized by the CEO of Alterity Therapeutics.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Alterity Therapeutics Ltd. on 6ix
Story so far
Earlier from Alterity Therapeutics
- Quarterly Activities/Appendix 4C Cash Flow Report
- Proposed issue of securities - ATH
- Notification regarding unquoted securities - ATH
- Notice of Annual General Meeting/Proxy Form
- Changes to Managing Director Terms of Employment
Later from Alterity Therapeutics
All Alterity Therapeutics news releasesFollow Alterity Therapeutics into a list and get an email when it puts out news.
Follow Alterity Therapeutics